HEALTH PROFESSIONAL · SOURCE READING

Synovial Sarcoma NOS (Poorly Differentiated, Spindle Cell, and Biphasic Varieties)

Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 21, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Tumors of Uncertain Differentiation

Synovial sarcoma accounts for 9% of soft tissue sarcomas in patients younger than 20 years (see Table 1).

Source links and citations

Table 1

Synovial sarcoma is one of the most common nonrhabdomyosarcomatous soft tissue sarcoma (NRSTS) in children and adolescents. In a review of the Surveillance, Epidemiology, and End Results (SEER) Program database from 1973 to 2005, 1,268 patients with synovial sarcoma were identified. Approximately 17% of these patients were children and adolescents, and the median age at diagnosis was 34 years.[4] In addition, in the Children's Oncology Group (COG) ARST0332 (NCT00346164) and European paediatric Soft Tissue Sarcoma Study Group (EpSSG) 2005 protocols, synovial sarcoma was the single most common histological subtype.[5]

Source links and citations

Continue within this section

Clinical presentation →Histological features, diagnostic evaluation, and genomic alterations →Prognostic factors →Treatment of synovial sarcoma →Recurrent synovial sarcoma NOS →Treatment options under clinical evaluation →

Studies cited in this source section

Source citation is not a determination that a study applies to you.

NCT00346164 · design, results and side effects

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice